A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Completed · Phase 1

Conditions studied: Neoplasms

In brief

The purpose of this study is to support the qualification of a replacement manufacturing site for DOXIL/CAELYX.

Key facts

Study ID

NCT02081495

Run by

Janssen Research & Development, LLC

People needed

35

Starts

2014-08-01

Expected to finish

2015-11-01

Last updated by the study team

2016-11-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Having advanced or refractory solid malignancies (histologically or cytologically confirmed advanced ovarian cancer failing platinum-based chemotherapy or metastatic breast cancer after failing approved life prolonging therapies or any solid malignancy that is metastatic or unresectable, and for which standard treatment is no longer an option)
• Eastern cooperative oncology group performance status 0 to 2
• Recovered from the acute toxicity (except alopecia and asymptomatic neuropathy) of any prior treatment
• Participants with prior doxorubicin (or other anthracyclines) or without any prior anthracylin exposure can also be included
• Agrees to protocol-defined use of effective contraception

You may not qualify if…

• Positive history of known brain metastases or leptomeningeal disease (spreading of cancer throughout the protective membranes covering the brain and spinal cord). Participants with brain metastases can only be enrolled if the following conditions are all met: 1) Brain metastases have been treated and stable for more than 4 weeks, 2) No evidence for progression or hemorrhage after treatment, 3) Steroid treatment was discontinued at least 2 weeks prior to first administration of DOXIL/CAELYX, and 4) Enzyme inducing anti-epileptic medicines were discontinued at least 4 weeks before first administration of DOXIL/CAELYX
• Use of an investigational medicine within 21 days or 5 half-lives (whichever is shorter) prior to the first dose of DOXIL/CAELYX
• Any major surgery, radiotherapy, or immunotherapy within the last 21 days. Chemotherapy regimens with delayed toxicity within the last 3 weeks (or within the last 6 weeks for prior nitrosourea or mitomycin C)
• Unstable angina or myocardial infarction within the preceding 12 months; congestive heart failure or any history of uncontrolled cardiac disease
• Having an uncontrolled infection and uncontrolled concurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or psychiatric illness/social situation that may potentially impair the participant's compliance with study procedures

Where it is running

• Study site — Los Angeles, California, United States
• Study site — Brussels, Belgium
• Study site — Wilrijk, Belgium
• Study site — Edmonton, Alberta, Canada
• Study site — Barcelona, Spain
• Study site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.